RAP 0.00% 20.5¢ raptor resources limited

Ann: Further Positive Results From Adult Clinical Study-RAP.AX, page-2

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,176 Posts.
    lightbulb Created with Sketch. 14
    - Achieved high levels of accuracy (91%-100%) for distinguishing adult patients
    with URTI, COPD, asthma or pneumonia from subjects with no discernible
    respiratory disease
    - Demonstrated differential diagnosis of asthma versus COPD, pneumonia
    versus asthma and pneumonia versus COPD at 88%-94% accuracy
    - Correctly detected lower respiratory tract disease in 84% of adult patients
    initially diagnosed as clear by experienced clinicians using stethoscopes
    - Finalised clinical protocol and confirmed three leading US hospitals for US
    paediatric study, SMARTCOUGH-C
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.